Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age

Jan de Kraker; Kees A. Hoefnagel; Arnauld C. Verschuur; Berthe van Eck; Hanneke M. van Santen; Huib N. Caron

doi:10.1016/j.ejca.2008.01.010

Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age

Jan de Kraker^*, Kees A. Hoefnagel, Arnauld C. Verschuur, Berthe van Eck, Hanneke M. van Santen, Huib N. Caron

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

78 Citations (Scopus)

Abstract

Purpose: To determine the response to radionuclide targeted therapy with I-131-metaiodobenzylguanidine (¹³¹I-MIBG) as induction therapy in high-risk neuroblastoma patients. Patients and methods: The protocol dictated at least two cycles of ¹³¹I-MIBG with a fixed dose of 7.4 and 3.7 GBq, respectively, followed by surgery, if feasible, or followed by neoadjuvant chemotherapy and surgery. This was followed by consolidation with four courses of chemotherapy myeloablative chemotherapy and autologous stem-cell transplantation (ASCT). Consolidation therapy with 13-cis-retinoic acid was given for 6 months. Results: Of 44 consecutive patients, 41 were evaluable after two courses of ¹³¹I-MIBG. The objective response rate at this point was 66%. In 24 patients, ¹³¹I-MIBG was continued as pre-operative induction treatment. Seventeen patients required additional chemotherapy before surgery. After pre-operative therapy and surgery, the overall response rate was 73%. Conclusion: First line ¹³¹I-MIBG-targeted therapy is a valuable tool in the treatment of MIBG-positive high-risk neuroblastoma patients.

Original language	English
Pages (from-to)	551-556
Number of pages	6
Journal	European Journal of Cancer
Volume	44
Issue number	4
DOIs	https://doi.org/10.1016/j.ejca.2008.01.010
Publication status	Published - 1 Mar 2008

Keywords

Iodine
Isotope
MIBG
Neoadjuvant therapy
Neuroblastoma
Nuclear medicine

Access to Document

10.1016/j.ejca.2008.01.010

Cite this

@article{d2aa0a2962d5449d96c9fb58dded7535,

title = "Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age",

abstract = "Purpose: To determine the response to radionuclide targeted therapy with I-131-metaiodobenzylguanidine (131I-MIBG) as induction therapy in high-risk neuroblastoma patients. Patients and methods: The protocol dictated at least two cycles of 131I-MIBG with a fixed dose of 7.4 and 3.7 GBq, respectively, followed by surgery, if feasible, or followed by neoadjuvant chemotherapy and surgery. This was followed by consolidation with four courses of chemotherapy myeloablative chemotherapy and autologous stem-cell transplantation (ASCT). Consolidation therapy with 13-cis-retinoic acid was given for 6 months. Results: Of 44 consecutive patients, 41 were evaluable after two courses of 131I-MIBG. The objective response rate at this point was 66%. In 24 patients, 131I-MIBG was continued as pre-operative induction treatment. Seventeen patients required additional chemotherapy before surgery. After pre-operative therapy and surgery, the overall response rate was 73%. Conclusion: First line 131I-MIBG-targeted therapy is a valuable tool in the treatment of MIBG-positive high-risk neuroblastoma patients.",

keywords = "Iodine, Isotope, MIBG, Neoadjuvant therapy, Neuroblastoma, Nuclear medicine",

author = "{de Kraker}, Jan and Hoefnagel, {Kees A.} and Verschuur, {Arnauld C.} and {van Eck}, Berthe and {van Santen}, {Hanneke M.} and Caron, {Huib N.}",

year = "2008",

month = mar,

day = "1",

doi = "10.1016/j.ejca.2008.01.010",

language = "English",

volume = "44",

pages = "551--556",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age

AU - de Kraker, Jan

AU - Hoefnagel, Kees A.

AU - Verschuur, Arnauld C.

AU - van Eck, Berthe

AU - van Santen, Hanneke M.

AU - Caron, Huib N.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Purpose: To determine the response to radionuclide targeted therapy with I-131-metaiodobenzylguanidine (131I-MIBG) as induction therapy in high-risk neuroblastoma patients. Patients and methods: The protocol dictated at least two cycles of 131I-MIBG with a fixed dose of 7.4 and 3.7 GBq, respectively, followed by surgery, if feasible, or followed by neoadjuvant chemotherapy and surgery. This was followed by consolidation with four courses of chemotherapy myeloablative chemotherapy and autologous stem-cell transplantation (ASCT). Consolidation therapy with 13-cis-retinoic acid was given for 6 months. Results: Of 44 consecutive patients, 41 were evaluable after two courses of 131I-MIBG. The objective response rate at this point was 66%. In 24 patients, 131I-MIBG was continued as pre-operative induction treatment. Seventeen patients required additional chemotherapy before surgery. After pre-operative therapy and surgery, the overall response rate was 73%. Conclusion: First line 131I-MIBG-targeted therapy is a valuable tool in the treatment of MIBG-positive high-risk neuroblastoma patients.

AB - Purpose: To determine the response to radionuclide targeted therapy with I-131-metaiodobenzylguanidine (131I-MIBG) as induction therapy in high-risk neuroblastoma patients. Patients and methods: The protocol dictated at least two cycles of 131I-MIBG with a fixed dose of 7.4 and 3.7 GBq, respectively, followed by surgery, if feasible, or followed by neoadjuvant chemotherapy and surgery. This was followed by consolidation with four courses of chemotherapy myeloablative chemotherapy and autologous stem-cell transplantation (ASCT). Consolidation therapy with 13-cis-retinoic acid was given for 6 months. Results: Of 44 consecutive patients, 41 were evaluable after two courses of 131I-MIBG. The objective response rate at this point was 66%. In 24 patients, 131I-MIBG was continued as pre-operative induction treatment. Seventeen patients required additional chemotherapy before surgery. After pre-operative therapy and surgery, the overall response rate was 73%. Conclusion: First line 131I-MIBG-targeted therapy is a valuable tool in the treatment of MIBG-positive high-risk neuroblastoma patients.

KW - Iodine

KW - Isotope

KW - MIBG

KW - Neoadjuvant therapy

KW - Neuroblastoma

KW - Nuclear medicine

UR - http://www.scopus.com/inward/record.url?scp=40249095844&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2008.01.010

DO - 10.1016/j.ejca.2008.01.010

M3 - Article

C2 - 18267358

AN - SCOPUS:40249095844

SN - 0959-8049

VL - 44

SP - 551

EP - 556

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 4

ER -

Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this